Crossmark

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

Crossref DOI link: https://doi.org/10.1038/nature21409

Published Online: 2017-03-08

Published Print: 2017-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guerriero, Jennifer L.

Sotayo, Alaba

Ponichtera, Holly E.

Castrillon, Jessica A.

Pourzia, Alexandra L.

Schad, Sara

Johnson, Shawn F.

Carrasco, Ruben D.

Lazo, Suzan

Bronson, Roderick T.

Davis, Scott P.

Lobera, Mercedes

Nolan, Michael A.

Letai, Anthony
License Information

Text and Data Mining valid from 2017-03-01
More Information

Article History

Received: 14 March 2016

Accepted: 19 January 2017

First Online: 8 March 2017

Competing interests

: This work was supported though a sponsored research agreement with GlaxoSmithKline to A.L. and J.L.G. S.P.D., M.L. and M.A.N. are GlaxoSmithKline employees.